Ultromics

The core of Ultromics' offering is the EchoGo® platform, a cloud-based, software-as-a-service (SaaS) system that uses AI to analyze routine cardiac ultrasound (echocardiogram) images. This platform is designed to integrate seamlessly with existing hospital IT infrastructure, such as PACS, without requiring new hardware installations. The business model is subscription-based, allowing healthcare providers to pay for the service based on the number of analyses performed. Ultromics serves clients ranging from small practices to large hospital systems and collaborates with pharmaceutical companies, research institutions, and government bodies.

The EchoGo® platform hosts several FDA-cleared medical devices. EchoGo® Heart Failure received FDA clearance in December 2022 and is designed to aid in the detection of Heart Failure with preserved Ejection Fraction (HFpEF), a condition that is often difficult to diagnose. The tool analyzes a single echocardiogram view to identify patterns indicative of HFpEF, providing clinicians with structured reports to support their diagnostic decisions. In November 2024, the company gained FDA clearance for EchoGo® Amyloidosis, a screening tool developed in partnership with Johnson & Johnson Innovative Medicine and Pfizer to facilitate the early detection of cardiac amyloidosis from a single echocardiogram clip. Another product, EchoGo Core, automates the calculation of key cardiac measurements like Ejection Fraction (EF) and Global Longitudinal Strain (GLS).

Since its inception, Ultromics has secured significant funding, including a $33 million Series B round in 2021 and a $55 million Series C round in 2025, with investors such as the Blue Venture Fund, Optum Ventures, GV (formerly Google Ventures), and major US health systems. The company has established numerous strategic partnerships, including with the Mayo Clinic for research, the UK's National Health Service (NHS), Johnson & Johnson, Pfizer, and the Foundation for the National Institutes of Health (FNIH).